drugset / Trial / NCT06166589
Second-line Zimberelimab and SIRIOX Chemotherapy for Patient With Previously AG Chemotherapy Treated Pancreatic Cancer
NaSingle-groupOpen-labelTreatment
Summary
This is a prospective, single arm, phase II clinical study investigating second-line Zimberelimab and SIROX chemotherapy for patient with previously AG chemotherapy treated pancreatic cancer.
Timeline
- Start
- 2024-01-01
- Primary completion
- 2026-01-01
- Completion
- 2027-01-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Irinotecan | Small molecule | 130 mg/m2 | — |
| Subject | Oxaliplatin | Small molecule | 60 mg/m2 | — |
| Subject | S-1 | Small molecule | 40 mg | — |
| Subject | S-1 | Small molecule | 60 mg | — |
| Subject | S-1 | Small molecule | 80 mg | — |
| Subject | S-1 | Small molecule | 100 mg | — |
| Subject | Zimberelimab | Monoclonal antibody | 240 mg | — |
Indications
No indication recorded.